Veracyte (VCYT)
(Delayed Data from NSDQ)
$23.76 USD
+0.34 (1.45%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $23.76 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VCYT 23.76 +0.34(1.45%)
Will VCYT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VCYT
Globus Medical (GMED) Global Sales, Innovation Aid Growth
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
Other News for VCYT
The 3 Best Personalized Nutrition Stocks to Buy Now
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Veracyte Shareholders Approve Directors and 2023 Plan Amendment
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness